MedTrace Logo

Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD

NCT01391715 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-01-18

No results posted yet for this study

Summary

To the best of our knowledge, there has been no randomized controlled trial to compare double dose PPI therapy with standard one dose PPI therapy for NERD patients. Thus, we hypothesize that a double dose PPI would accelerate and sustain the control of symptom in NERD patients.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

rabeprazole

rabeprazole 20mg bid per day for 2 weeks

DRUG

standard dose rabeprazole

rabeprazole 20mg qd per day for 2 weeks

Sponsors & Collaborators

  • Inje University

    lead OTHER

Principal Investigators

  • Tae Oh Kim, M.D. PhD. · Internal Medicine, Haeundae Paik Hospital

  • Eun Hee Seo, M.D · Internal Medicine, Haeundae Paik Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-10-31
Completion
2012-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01391715 on ClinicalTrials.gov